Physician profile
Melissa M Hardesty
NPI 1821092362
$85,587.97
in general payments reported to CMS, 2019-2025
23 companies · $9,112 in 2025
The $9,112 reported for 2025 was more than what 90% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $555 · 2020: $262 · 2021: $15K · 2022: $22K · 2023: $16K · 2024: $24K · 2025: $9,112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $41K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,270 · Food and Beverage: $2,262 · Travel and Lodging: $455 · Education: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $41,070.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,270.00 |
| Food and Beverage | $2,261.91 |
| Travel and Lodging | $454.98 |
| Education | $164.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $32,547.45 | 2019-2025 | Enhertu, Lynparza, Imfinzi |
| Glaxosmithkline, LLC. | $30,636.47 | 2020-2025 | Zejula, Jemperli |
| Intuitive Surgical, INC. | $6,100.74 | 2019-2024 | Da Vinci Surgical System |
| Merck Sharp & Dohme LLC | $5,076.04 | 2019-2024 | Keytruda, Lynparza |
| Takeda Pharmaceuticals U.S.A., INC. | $4,380.00 | 2022 | |
| Eisai INC. | $3,416.31 | 2022-2025 | |
| Daiichi Sankyo INC. | $1,924.53 | 2023-2025 | Enhertu |
| Abbvie INC. | $353.53 | 2025 | |
| Seagen INC. | $331.85 | 2021-2025 | Tivdak |
| Genentech USA, INC. | $145.16 | 2019 | |
| Immunogen, INC. | $125.00 | 2023 | Elahere |
| Pharmaand Gmbh | $122.89 | 2025 | Rubraca |
| Tesaro, INC. | $106.09 | 2019 | |
| Pfizer INC. | $91.10 | 2024-2025 | |
| Astellas Pharma US INC | $81.74 | 2023-2024 | Veozah |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Clovis Oncology, INC. | $54.71 | 2021-2022 | |
| Heron Therapeutics, INC. | $30.76 | 2025 | Zynrelef |
| Novartis Pharmaceuticals Corporation | $30.33 | 2025 | |
| Becton, Dickinson and Company | $17.76 | 2019 | |
| Tactile Systems Technology INC | $15.51 | 2021 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Hardesty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.